Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
- Biological: Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 1)
- Biological: Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 2)
- Biological: Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 3)
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Peng Wan
- Phone Number: 022-58213600-6051
- Email: peng.wan@cansinotech.com
Study Locations
-
-
Henan
-
Xuchang, Henan, China, 461500
- Changge Center for Disease Control and Prevention
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 2 months of age (60~89 days), willing to provide identification documents;
- The legal guardian or delegate has given informed consent, voluntarily signed the informed consent form, and can comply with the requirements of the clinical research protocol.
Exclusion Criteria:
First dose exclusion criteria
- Persons who have received a vaccine containing the DPT classified vaccine;
- Premature labor (delivery before 37th week of gestation), low birth weight 60 (birth weight <2500g);
- Those with abnormal labor and delivery, history of asphyxia rescue, history of neurological damage;
- Who have had one of the pertussis, diphtheria or tetanus diseases;
- Who have had household contact with an individual diagnosed with pertussis, diphtheria, or tetanus disease in the past 30 days;
- Have a history of allergy to vaccines or vaccine components and severe side reactions to vaccines, such as hives, dyspnea, angioneurotic edema, and other allergic reactions;
- Persons with a history of seizures, convulsions, convulsions, or cerebral palsy; or a history or family history of psychiatric illness; or other progressive neurologic disorders;
- Have been diagnosed with an immunodeficiency, Human Immunodeficiency Virus (HIV) infection, lymphoma, leukemia, Systemic Lupus Erythematosus (SLE), Juvenile Rheumatoid Arthritis ( Juvenile Rheumatoid Arthritis (JRA) or other autoimmune diseases;
- Any condition resulting in absence of spleen, defective spleen function;
- Known or suspected acute illness or severe chronic disease (including: severe respiratory disease, severe cardiovascular disease, liver or kidney disease, severe skin disease, malignancy, etc.); or in an acute exacerbation of a chronic disease;
- Physician-diagnosed coagulation abnormalities (e.g., coagulation factor deficiencies, coagulopathies, platelet abnormalities) or significant bruising or coagulation disorders;
- Immunosuppressive or modifying agents, cytotoxic consecutive therapy for more than 10 days (except inhaled and topical steroids) within 2 months prior to receiving the test vaccine;
- Received blood products (other than hepatitis B immune globulin) within 2 months prior to receiving the test vaccine;
- Participated or planning to participate in any other drug or vaccine clinical study;
- Has received an injectable live attenuated vaccine within 14 days or another vaccine within 7 days prior to receiving the test vaccine;
- Axillary temperature >37.3°C prior to vaccination;
- Any other factor that, in the investigator's judgment, makes the subject unsuitable for participation in a clinical trial.
Exclusion Criteria for Doses 2,3
- Persons who have had a severe allergic reaction following a previous dose of vaccine;
- Persons with serious adverse reactions causally related to the previous dose of vaccination;
- Those with a newly identified or newly occurring condition after the first dose of vaccination that does not meet the inclusion criteria for the first dose or meets the exclusion criteria for the first dose, as determined by the investigator for continued participation in the study;
- Other reasons for exclusion as determined by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental vaccine group A, 2 months old
3 doses of DTcP vaccine (0.5 ml) on Day 0and Month 2,4
|
Three doses of basic immunization were completed at 2, 4 and 6 months of age
|
|
Experimental: Experimental vaccine group B, 2 months old
3 doses of DTcP vaccine (0.5 ml) on Day 0and Month 2,4
|
Three doses of basic immunization were completed at 2, 4 and 6 months of age
|
|
Experimental: Experimental vaccine group C, 2 months old
3 doses of DTcP vaccine (0.5 ml) on Day 0and Month 2,4
|
Three doses of basic immunization were completed at 2, 4 and 6 months of age
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Geometric Mean Concentration (GMC) of serum anti-PT, FHA, PRN, DT, and TT antibodies in 2-month-old subjects with three different batches of the trial vaccine.
Time Frame: 30 days after vaccination
|
30 days after vaccination
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Seroconversion rate of serum anti-PT, FHA, PRN, DT, and TT antibodies in 2-month-old subjects with three different batches of the trial vaccine.
Time Frame: 30 days after vaccination
|
30 days after vaccination
|
|
Seropositivity rate of serum anti-PT, FHA, PRN, DT, and TT antibodies in 2-month-old subjects with three different batches of the trial vaccine
Time Frame: 30 days after vaccination
|
30 days after vaccination
|
|
Incidence of solicited adverse reactions for each vaccine dose in 2-month-old subjects.
Time Frame: Within 30 minutes post-vaccination
|
Within 30 minutes post-vaccination
|
|
Incidence of solicited adverse reactions for each vaccine dose in 2-month-old subjects.
Time Frame: Within 0-7 days
|
Within 0-7 days
|
|
Incidence of unsolicited adverse reactions for each vaccine dose in 2-month-old subjects.
Time Frame: Within 0-30 days
|
Within 0-30 days
|
|
Incidence of Serious Adverse Events (SAEs) in 2-month-old subjects.
Time Frame: From first vaccination to 30 days after the third dose
|
From first vaccination to 30 days after the third dose
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yanxia Wang, Henan Center for Disease Control and Prevention
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CTP-DTcP-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.